PDCD1LG2 and neoplasm: Among the immune checkpoint inhibitor therapies, those targeting the interactions between the immunosuppressive receptor expressed on the surface of T cells, namely Programmed Death-1 (PD-1) and its ligands PD-L1 and PD-L2, are considered promising, especially in tumors with high PD-1 expression and tumor-infiltrating lymphocytes (TILs) [127].